Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$15.12 USD
+0.39 (2.65%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $15.12 0.00 (0.00%) 5:12 PM ET
4-Sell of 5 4
B Value A Growth A Momentum A VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CPRX 15.12 +0.39(2.65%)
Will CPRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CPRX
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Other News for CPRX
20 companies screened for quality in a cheap part of the stock market
Edgewise gets EU orphan drug status for muscular dystrophy drug
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)